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Hematocrit trial
To the Editor:
We read with interest the report by
Ootaki and associates,1 as well as the
correspondence by Shuhaiber2 in refer-
ence to the article by Habib and col-
leagues.3 Ootaki and coworkers1 applied
a transfusion protocol in which blood
was not transfused during cardiopulmo-
nary bypass unless hematocrit was less
than 15%. They found that patients with a
hematocrit of less than 20% had a higher
lactate level than patients with a higher
hematocrit but imply that this has no
functional significance.
In their critique of the article by Habib
and associates,3 which emphasized the
value of the lowest hematocrit as a predic-
tor of outcome, Shuhaiber2 implied that a
hematocrit of 20% is a useful transfusion
trigger. They also called for a prospective
randomized study of hematocrit, as did
Habib’s group.
At the 2002 meeting of the American
Association for Thoracic Surgery, we pre-
sented the results of a prospective random-
ized trial of 2 hemodilution strategies.4
This study was shut down by the Data and
Safety Monitoring Board of the National
Institutes of Health because of a strongly
positive outcome. Infants who had a mean
hematocrit of 27.8%  3.2% (n  73) had
significantly better motor skills at 1 year of
age relative to patients whose lowest he-
matocrit on bypass was 21.5%  2.9%
(n  74). A significantly greater percent-
age of patients at 1 year of age were clas-
sified as developmentally delayed with re-
spect to motor skills relative to patients
perfused at a higher hematocrit. The lactate
level 1 hour after bypass was significantly
lower with the higher hematocrit.
The findings of our prospective ran-
domized study are consistent with several
previous reports derived from our labo-
ratory work in this area.5-7 Studies using
near-infrared spectroscopy suggest that
acute hemodilution during cardiopulmo-
nary bypass results in cerebral hypoxia. It
is important to remember, before discard-
ing the significance of our clinical trial as
being irrelevant to adults because it was
performed in infants, that the mature
brain is significantly more sensitive to
hypoxic injury than the neonatal and in-
fant brain. Nevertheless, we strongly en-
dorse the call for a prospective random-
ized trial of hematocrit in adults
undergoing cardiopulmonary bypass, in-
cluding sensitive end points such as as-
sessment for cognitive dysfunction. In
the meantime, we strongly recommend
that a hematocrit of at least 25% and
preferably closer to 30% should be used
during cardiopulmonary bypass.
Richard A. Jonas, MD
Department of Cardiovascular Surgery
Children’s National Medical Center
Washington, DC 20010
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Randomized prospective trial for
blood transfusion during adult
cardiopulmonary bypass surgery
To the Editor:
Hemoglobin dilution is an expected physi-
ologic response during cardiopulmonary
bypass (CPB) surgery. Current contro-
versy, however, centers around this ques-
tion: what is a safe hematocrit level during
CPB before the patient sustains less than an
expected outcome? The main reason for the
lack of consensus regarding blood transfu-
sion may stem from the lack of a direct
cause (hematocrit level) and effect (mor-
bidity and mortality) relationship or an as-
sociation or both causality and association.
Although it has been found that low pre-
operative hemoglobin levels are correlated
with poorer outcome,1 it does not mean
that correcting this number will result in
improved outcome. This same argument
holds true for intraoperative hematocrits
with the understanding that new-onset in-
traoperative anemia is reversible and
mainly caused by dilution, whereas preop-
erative anemia is pathologic and mainly
caused by nondilutional processes. Also,
despite understanding the reversibility con-
cept, most decisions of intraoperative
transfusion stem from personal and institu-
tional experience, with no defined dimen-
sions. In May 2004, the National Heart,
Lung, and Blood Institute working group
published an executive summary regarding
future directions in cardiac surgery.2 Cre-
ating a cardiovascular surgery clinical re-
search network was one of the pillars, and
I hope that the working group and the Na-
tional Institutes of Health–sponsored work-
shop for neurocognitive changes after car-
diac surgery will consider this trial an
important direction toward filling an exist-
ing critical gap.
Why Is a Hematocrit Trial Timely?
The patient’s physiologic status must be
the underlying cause for a transfusion, and
the outcome of the transfusion (effect)
must also be considered. The practicing
surgeon, including those in training, is cur-
rently confused with the paradigm of cause
and effect that seems to argue that mortal-
ity is higher among patients with low he-
matocrit (25% in women and 23% in
men3,4) and high hematocrit (34%).5
Randomization is lacking in the adult car-
diac surgery group thus far, despite a clear
benefit of increased hematocrit for neuro-
logic outcome in pediatric heart surgery
(mean intraoperative hematocrit: 27.8% vs
21.5%).6
Moreover, despite the benefit of in-
creased oxygen-carrying capacity with
increased hematocrit, we must be aware
that blood transfusions expose patients to
a variety of potential cellular and hu-
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